Skip to content
biotechnology hero image
biotechnology hero image

Biotechnology

Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.

Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.

We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.

We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.

News & insights

A selection of credit cards

Publications: 07 OCTOBER 2020

Debt finance remains on tap for buyers of Covid-19-robust businesses

The Covid-19 pandemic may have changed the dynamics of debt markets, but financing remains readily available for companies in sectors that have proven resilient throughout the Covid-19 crisis.

Read more
A drop of liquid being placed into a test tube

News: 18 SEPTEMBER 2020

Allen & Overy advises Apax Partners and its portfolio company Neuraxpharm on the acquisition of Buccolam® Assets

We have advised Apax Partners and its portfolio company Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), on the acquisition of the…

Read more

Publications: 29 JULY 2020

A hard pill to swallow: Belgian Court of Cassation provides clarity on patient informed consent

Setting the stage Since long, discussions in Belgium have been ongoing as to who needs to prove that a patient was sufficiently informed about his/her treatment and its potential complications. With…

Read more
A drop of liquid falling into a test tube

Publications: 08 JULY 2020

Pipeline gaps and digital will drive life sciences deals

Often seen as a safe haven sector in times of crisis, the life sciences have not only been centre stage during the Covid-19 coronavirus crisis but are riding it out well.

Read more

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2020

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.